The future of retina: New targets and more durable solutions

The treatment landscape for retinal diseases is advancing rapidly, with novel therapies and clinical trials offering new hope for patients with conditions such as neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Among the promising areas of research are innovative approaches targeting pan-vascular endothelial growth factor (VEGF) inhibition.